Clinical Trials on Transitional Cell Carcinoma in China

Total 7422 results

Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
Peking University Cancer Hospital & Institute

Unknown

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Jun Guo

Not yet recruiting

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma

China
Sichuan Provincial People's Hospital

Recruiting

18F-LN1 PET/CT in Urothelial Carcinomas

Urothelial Carcinoma

China
Peking University First Hospital

Recruiting

Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC

Urothelial Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Urothelial Carcinoma

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
Lee's Pharmaceutical Limited

Recruiting

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Changhai Hospital
RenJi Hospital; West China Hospital; Tongji Hospital; Qilu Hospital of Shandong... and other collaborators

Recruiting

A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up

Urothelial Carcinoma

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
Tianjin Medical University Second Hospital

Recruiting

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Lee's Pharmaceutical Limited

Active, not recruiting

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Solid Tumor | Urothelial Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
First Affiliated Hospital of Zhejiang University

Not yet recruiting

18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

18F-HER2 PET

China
AnchorDx Medical Co., Ltd.
Peking University First Hospital; Peking Union Medical College Hospital; Peking... and other collaborators

Recruiting

Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection

Upper Tract Urothelial Carcinoma

China
RenJi Hospital

Unknown

Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

China
Qinghua Xia,Prof

Not yet recruiting

A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion

Chemotherapy Effect

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Jinling Hospital, China

Recruiting

A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma (1)

Carcinoma | Upper Tract Urothelial Carcinoma | UTUC

China
Xiangya Hospital of Central South University
Hunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaborators

Completed

Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC

High-Grade Upper Tract Urothelial Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Carcinoma, Transitional Cell | HER-2 Gene Amplification

China
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China
RenJi Hospital
Xiangya Hospital of Central South University; Shanghai Zhongshan Hospital; West... and other collaborators

Recruiting

Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma

China
RemeGen Co., Ltd.

Completed

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Ruijin Hospital
Hangzhou Genetron Medical Laboratory Co., Ltd.

Recruiting

Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS

Urothelial Carcinoma

China
Chunguang yang (101937)

Recruiting

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Urothelial Carcinoma | Radical Cystectomy

China
BeiGene

Recruiting

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Urothelial Carcinoma

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Urothelial Carcinoma

Japan
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Advanced Melanoma | Advanced Urothelial Carcinoma

China
Peking University First Hospital

Unknown

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients

Upper Tract Urothelial Carcinoma | Bladder Recurrence | Nephroureterectomy

China
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer

United States, China, Korea, Republic of
Peking University First Hospital

Unknown

Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients

Upper Tract Urothelial Carcinoma | Bladder Recurrence

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Peking University First Hospital

Unknown

Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma) (UTUC)

Recurrence | Metastasis | Upper Tract Urothelial Carcinoma | Lymph Node Dissection

China
RenJi Hospital
Peking University First Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Circulating Tumour DNA and Urine Tumor DNA Detection of Minimal Residual Disease in Locally Advanced Upper Tract Urothelial Carcinoma With Radical Nephroureterectomy: A Cohort Study

Muscle Invasive Upper Tract Urothelial Carcinoma

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Melanoma | Urothelial Carcinoma

China
Tianjin Medical University Second Hospital

Not yet recruiting

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Urogenital Neoplasms | Urothelial Carcinoma | Antineoplastic Agents | Gemcitabine | Cisplatin | Anlotinib | Carboplatin

China
RenJi Hospital
Shanghai Pudong Hospital; Shanghai Pudong New Area Gongli Hospital

Unknown

Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma

Intravesical Instillation

China
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China

Clinical Trials on Transitional Cell Carcinoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations